Core Insights - Defence Therapeutics Inc. will present new scientific data on its Accum® technology at the World ADC Conference in San Diego, highlighting its potential to enhance the efficacy of antibody-drug conjugates (ADCs) [1][2] Company Overview - Defence Therapeutics is a biotechnology company focused on drug delivery technologies, specifically developing next-generation ADC products using its proprietary Accum® platform [5] - The Accum® technology is designed to improve intracellular delivery and endosomal escape of therapeutic payloads, addressing limitations of current ADCs and enabling higher potency with reduced off-target toxicity [2][5] Scientific Findings - New results to be presented at the conference demonstrate Accum®'s ability to significantly improve the therapeutic index of ADCs, allowing for more efficient delivery of toxic payloads directly into cancer cells [2][3] - The Chief Scientific Officer of Defence Therapeutics expressed excitement about sharing these findings with the scientific community and advancing research towards next-generation targeted therapies [3] Conference Details - The World ADC Conference is a premier event for ADC innovation, featuring 1,400 industry attendees and over 170 world-class speakers, providing significant networking opportunities [4]

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

Core Insights - Defence Therapeutics Inc. has opened its first U.S. laboratory in the Boston-Cambridge area, marking its initial physical presence in the United States and reinforcing its commitment to advanced research and development in biotechnology [1][2][3] Company Expansion - The new laboratory is located at Cambridge Scientific Labs in Watertown, which will facilitate the development and optimization of the company's proprietary Accum® technology for antibody-drug conjugates (ADCs) [2] - Establishing a presence in the Boston-Cambridge area provides access to top-tier scientific resources and collaboration opportunities within the region's renowned biotech ecosystem [2] Strategic Importance - The CEO of Defence Therapeutics emphasized that this expansion is a significant milestone, positioning the company at the heart of the global biotech community and supporting its mission to advance the Accum® platform for next-generation ADCs [3] - The Cambridge Scientific Labs location will serve as a short-term base while the company evaluates options for a long-term facility in the area [2][3] Company Overview - Defence Therapeutics is a publicly-traded clinical-stage biotechnology company focused on developing next-generation radio-immuno-conjugate and ADC products using its proprietary ACCUM® technology, which enables precision delivery to target cells, enhancing efficacy against cancer [3]